Advanced Search

 

Study ID Status Title Patient Level Data
103815 Completed An open, prospective, non-prophylactic, non therapeutic study for the detection and characterisation of varicella zoster virus collected from dermal lesions of patients who are diagnosed of having varicella/breakthrough varicella
103954 Completed Study to evaluate the safety, reactogenicity & immunogenicity of a booster dose of GSK Biologicals’ Hib-MenC given with Priorix™, vs Hib-MenC or Priorix™ only, in toddlers (13–14 m) primed with 3 doses of Hib (as part of a DTPa –containing vaccine) & MenC-CRM197 conjugate vaccines. Study Listed on ClinicalStudyDataRequest.com
103967 Completed A Phase I/IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine in infants living in a malaria-endemic region
103974 (primary study) Completed Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months Study Listed on ClinicalStudyDataRequest.com
103992 Completed Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Study Listed on ClinicalStudyDataRequest.com
103996 Completed Observer-blind, single center, controlled study of 2 doses of various formulations of the WRAIR live attenuated tetravalent dengue vaccine compared to a placebo control, administered on a 0-6-month schedule, to healthy adults
103997 Completed An open, non-comparative study to evaluate the efficacy and safety of AUGMENTIN 1gm (875mg Amoxicillin/125mg Clavulanic acid) po q 12 hours in the treatment of uncomplicated skin and soft tissue infections in Pakistan
104005 Completed Phase IIIb, open, randomized, multicenter study to assess the immunogenicity & safety of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in Indian infants when given at 6-10-14 weeks of age or at 2-4-6 months of age Study Listed on ClinicalStudyDataRequest.com
104020 Completed Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Study Listed on ClinicalStudyDataRequest.com
104021 Completed A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Study Listed on ClinicalStudyDataRequest.com
104065 Completed Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib Study Listed on ClinicalStudyDataRequest.com
104083 Completed Phase III multicentric open study to evaluate immunological memory induced by 3-dose primary vaccination followed by booster dose of GSK Biologicals' 11-valent conjugate pneumococcal vaccine compared to unprimed subjects by giving 1 dose of Aventis Pasteur's Pneumo 23
104124 Completed Assess the safety and reactogenicity of GSK Biologicals Hib vaccine co-administered with Chinese local DTPw vaccine when compared to Chinese local DTPw vaccine administered alone, in healthy infants at 3,4 & 5 months of age
104147 Completed A multicentric, post-marketing surveillance to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals Hepatitis A vaccine administered in Korean population.
104154 Completed Open, prospective study of the safety of GSK Biologicals' Boostrix® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) administered to a cohort of adolescents in a US Health Maintenance Organization (HMO)
104228 Completed Post-marketing clinical study on PAXIL Tablet in patients with depression or depressive mood - A study on combination of PAXIL Tablet and benzodiazepines
104246 Completed A 2-year Observational study to evaluate safety of Seretide 50/500μg twice daily administered by DISKUS, in patients with COPD
104274 Completed A randomized, open-label, parallel-group study, to assess the pharmocodynamic effect on dihydrotestosterone regulated gene expression, longitudinally and in a dose dependent manner, of 0.5mg and 3.5mg dutasteride administered orally once daily, for one year in men with symptomatic benign prostatic hyperplasia and during a two month period between baseline and radical prostatectomy in men with biopsy-proven, clinically localized prostate cancer
104297 Completed An open study for a 2-year period to confirm the safety and immunogenicity of the candidate malaria vaccine RTS,S/AS02A in Mozambican children aged 1 to 4 years at the time of first vaccine dose. Study Listed on ClinicalStudyDataRequest.com
104298 Completed A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine, when incorporated into an Expanded Program on Immunization (EPI) regimen that includes DTPw/Hib in infants living in a malaria-endemic region.
104385 Completed A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo. Study Listed on ClinicalStudyDataRequest.com
104387 Completed Demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, multidose Engerix™-B to that of monodose Engerix™-B when administered according to 0,1,6 mths schedule in healthy adults aged ≥ 18 yrs Study Listed on ClinicalStudyDataRequest.com
104389 Completed Blinded, randomised, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella candidate vaccine given to healthy children in their second year of life Study Listed on ClinicalStudyDataRequest.com
104435 Completed Post-Authorization Safety Study (PASS) of Post-Marketing Surveillance for Intussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social (IMSS) in Mexico
104437 Completed A phase III, observer-blind, randomized study to evaluate the immunogenicity and safety of Fluarix™ (GlaxoSmithKline Biologicals) compared with Fluzone® (Aventis Pasteur) administered intramuscularly in adults 18 years and older in the U.S. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.